Royalty Pharma Declares Third-Quarter 2021 Dividend
July 16 2021 - 9:00AM
The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has
approved the payment of a dividend for the third quarter of 2021 of
$0.17 per class A ordinary share.
The dividend will be paid on September 15, 2021, to shareholders
of record at the close of business on August 20, 2021.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of
biopharmaceutical royalties and a leading funder of innovation
across the biopharmaceutical industry, collaborating with
innovators from academic institutions, research hospitals and
not-for-profits through small and mid-cap biotechnology companies
to leading global pharmaceutical companies. Royalty Pharma has
assembled a portfolio of royalties which entitles it to payments
based directly on the top-line sales of many of the industry’s
leading therapies. Royalty Pharma funds innovation in the
biopharmaceutical industry both directly and indirectly - directly
when it partners with companies to co-fund late-stage clinical
trials and new product launches in exchange for future royalties,
and indirectly when it acquires existing royalties from the
original innovators. Royalty Pharma’s current portfolio includes
royalties on more than 45 commercial products, including AbbVie and
J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s
Tysabri, J&J’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia,
Novartis’ Promacta, and Vertex’s Kalydeco, Orkambi, Symdeko and
Trikafta, and nine development-stage product candidates. For more
information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and
Communications
+1 (212) 883-6772ir@royaltypharma.com
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Sep 2023 to Sep 2024